Daré Bioscience Secures $908K NIH Grant to Advance Preterm Birth Prevention Program
Event summary
- Daré Bioscience received a $908,000 grant from NICHD to advance DARE-PTB2, an investigational program for preventing preterm birth.
- The grant includes potential for an additional $1.3 million in future-year support for preclinical studies.
- DARE-PTB2 aims to address a significant unmet medical need with no FDA-approved therapeutic options currently available.
- The program builds on previous NICHD funding of $400,000 received in July 2023 for preclinical development.
The big picture
The NIH grant underscores the critical need for innovative solutions in preterm birth prevention, an area with significant unmet medical needs. Daré's ability to secure non-dilutive funding highlights its strategic focus on leveraging external support to advance its pipeline. The broader industry trend of increasing investment in women's health research positions Daré to potentially capitalize on growing awareness and demand for targeted therapeutic solutions.
What we're watching
- Funding Execution
- Whether Daré can effectively utilize the NIH grant to advance DARE-PTB2 through preclinical stages and secure the additional $1.3 million in future funding.
- Regulatory Pathway
- The pace at which DARE-PTB2 progresses toward clinical trials and potential FDA approval, given the current lack of therapeutic options for preterm birth.
- Strategic Focus
- How Daré balances its focus on DARE-PTB2 with other programs in its women's health portfolio, particularly given the early-stage nature of this investigational program.
Related topics